Sort by

Send to

Choose Destination

Search results

Items: 16


Identification of Claudin 1 Transcript Variants in Human Invasive Breast Cancer.

Blanchard AA, Zelinski T, Xie J, Cooper S, Penner C, Leygue E, Myal Y.

PLoS One. 2016 Sep 20;11(9):e0163387. doi: 10.1371/journal.pone.0163387.


Cell-Specific Cre Strains For Genetic Manipulation in Salivary Glands.

Maruyama EO, Aure MH, Xie X, Myal Y, Gan L, Ovitt CE.

PLoS One. 2016 Jan 11;11(1):e0146711. doi: 10.1371/journal.pone.0146711.


Claudin 1 in Breast Cancer: New Insights.

Zhou B, Moodie A, Blanchard AA, Leygue E, Myal Y.

J Clin Med. 2015 Nov 27;4(12):1960-76. doi: 10.3390/jcm4121952. Review.


Towards further defining the proteome of mouse saliva.

Blanchard AA, Ezzati P, Shamshurin D, Nistor AC, Leygue E, Wilkins JA, Myal Y.

Proteome Sci. 2015 Feb 25;13:10. doi: 10.1186/s12953-015-0068-3.

Free PMC Article

Sirtuin-3 (SIRT3) Protein Attenuates Doxorubicin-induced Oxidative Stress and Improves Mitochondrial Respiration in H9c2 Cardiomyocytes.

Cheung KG, Cole LK, Xiang B, Chen K, Ma X, Myal Y, Hatch GM, Tong Q, Dolinsky VW.

J Biol Chem. 2015 Apr 24;290(17):10981-93. doi: 10.1074/jbc.M114.607960.


Claudin 1 expression in basal-like breast cancer is related to patient age.

Blanchard AA, Ma X, Dueck KJ, Penner C, Cooper SC, Mulhall D, Murphy LC, Leygue E, Myal Y.

BMC Cancer. 2013 May 30;13:268. doi: 10.1186/1471-2407-13-268.


Claudin 1 in breast tumorigenesis: revelation of a possible novel "claudin high" subset of breast cancers.

Myal Y, Leygue E, Blanchard AA.

J Biomed Biotechnol. 2010;2010:956897. doi: 10.1155/2010/956897.


Steroid Receptor RNA Activator Protein (SRAP): a potential new prognostic marker for estrogen receptor-positive/node-negative/younger breast cancer patients.

Yan Y, Skliris GP, Penner C, Chooniedass-Kothari S, Cooper C, Nugent Z, Blanchard A, Watson PH, Myal Y, Murphy LC, Leygue E.

Breast Cancer Res. 2009;11(5):R67. doi: 10.1186/bcr2359.


Increasing the relative expression of endogenous non-coding Steroid Receptor RNA Activator (SRA) in human breast cancer cells using modified oligonucleotides.

Cooper C, Guo J, Yan Y, Chooniedass-Kothari S, Hube F, Hamedani MK, Murphy LC, Myal Y, Leygue E.

Nucleic Acids Res. 2009 Jul;37(13):4518-31. doi: 10.1093/nar/gkp441.


Expression of small breast epithelial mucin (SBEM) protein in tissue microarrays (TMAs) of primary invasive breast cancers.

Skliris GP, Hubé F, Gheorghiu I, Mutawe MM, Penner C, Watson PH, Murphy LC, Leygue E, Myal Y.

Histopathology. 2008 Feb;52(3):355-69. doi: 10.1111/j.1365-2559.2007.02955.x.


Expression of two breast-specific molecules in the lung.

Hube F, Myal Y, Leygue E, Rollin J, Gruel Y.

J Mol Diagn. 2006 Jul;8(3):390-1; author reply 391-3. No abstract available.


Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer.

Nistor A, Watson PH, Pettigrew N, Tabiti K, Dawson A, Myal Y.

BMC Clin Pathol. 2006 Jan 18;6:2.


Expression analysis of the mouse S100A7/psoriasin gene in skin inflammation and mammary tumorigenesis.

Webb M, Emberley ED, Lizardo M, Alowami S, Qing G, Alfia'ar A, Snell-Curtis LJ, Niu Y, Civetta A, Myal Y, Shiu R, Murphy LC, Watson PH.

BMC Cancer. 2005 Feb 17;5:17.


Age-related differences in 1p and 19q deletions in oligodendrogliomas.

Myal Y, Del Bigio MR, Rhodes RH.

BMC Clin Pathol. 2003 Dec 11;3(1):6.


A BglII RFLP at the human prolactin gene locus on chromosome 6 (PRL).

Myal Y, DiMattia GE, Gregory CA, Friesen HG, Hamerton JL, Shiu RP.

Nucleic Acids Res. 1991 Mar 11;19(5):1167. No abstract available.


TaqI and RsaI RFLP's at the prolactin inducible protein (PIP) locus on chromosome 7.

Myal Y, Gregory CA, Karpan C, Hamerton JL, Shiu RP.

Nucleic Acids Res. 1989 Jul 25;17(14):5879. No abstract available.

Items per page

Supplemental Content

Loading ...
Support Center